Sanofi Aventis Us Company Profile

✉ Email this page to a colleague

▶ Start for $1
Remove trial restrictions

SANOFI AVENTIS US has one hundred and twenty-two approved drugs.

There are eleven US patents protecting SANOFI AVENTIS US drugs.

There are two hundred and fifty-seven patent family members on SANOFI AVENTIS US drugs in fifty-three countries and one hundred and ten supplementary protection certificates in nineteen countries.

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	CHRONULAC	lactulose	SOLUTION;ORAL	017884-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No		See Plans and Pricing				See Plans and Pricing
Sanofi Aventis Us	SLO-PHYLLIN	theophylline	CAPSULE, EXTENDED RELEASE;ORAL	085205-001	May 24, 1982		DISCN	No	No		See Plans and Pricing				See Plans and Pricing
Sanofi Aventis Us	SLO-PHYLLIN	theophylline	TABLET;ORAL	085202-001	Approved Prior to Jan 1, 1982		DISCN	No	No		See Plans and Pricing				See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try it Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	ARAVA	leflunomide	TABLET;ORAL	020905-003	Sep 10, 1998	4,284,786	See Plans and Pricing
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-004	Mar 27, 1998	5,389,618	See Plans and Pricing
Sanofi Aventis Us	JEVTANA KIT	cabazitaxel	SOLUTION;INTRAVENOUS	201023-001	Jun 17, 2010	5,438,072	See Plans and Pricing
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Tablets	7 mg and 14 mg	➤ Subscribe	2016-09-12
➤ Subscribe	Tablets	300 mg/25 mg	➤ Subscribe	2006-06-06
➤ Subscribe	Tablets	400 mg	➤ Subscribe	2013-07-01
➤ Subscribe	Injection	5 mg/mL, 10 mL and 20 mL vials	➤ Subscribe	2007-02-09
➤ Subscribe	Injection	200 mg/40 mL	➤ Subscribe	2007-07-16
➤ Subscribe	Injection	100 mg/mL, 3 mL vials	➤ Subscribe	2006-12-07
➤ Subscribe	Extended-release Tablets	12.5 mg	➤ Subscribe	2006-01-19
➤ Subscribe	Tablets	150 mg/12.5 mg and 300 mg/12.5 mg	➤ Subscribe	2004-11-10
➤ Subscribe	Tablets	75 mg, 150 mg and 300 mg	➤ Subscribe	2004-05-25
➤ Subscribe	Tablets	300 mg	➤ Subscribe	2009-03-04
➤ Subscribe	Injection	40 mg/mL, 0.5 mL and 2 mL vials	➤ Subscribe	2009-06-30
➤ Subscribe	For Injection	50 mg/vial and 100 mg/vial	➤ Subscribe	2007-02-09
➤ Subscribe	Injection	5 mg/mL, 40 mL vial	➤ Subscribe	2011-03-23
➤ Subscribe	Extended-release Tablets	6.25 mg	➤ Subscribe	2006-02-24

Patent Number	Expiration Date
See Plans and Pricing	See Plans and Pricing

Subscribe to access the full database, or Try it Free
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2768484	132019000000144	Italy	See Plans and Pricing	PRODUCT NAME: DAUNORUBICINA E CITARABINA(VYXEOS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1308, 20180827
1110543	08C0004	France	See Plans and Pricing	PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
0100718	96C0006	Belgium	See Plans and Pricing	PRODUCT NAME: TILUDRONATE DISODIQUE EXPRIME EN ACIDE TILUDRONIQUE; NAT. REGISTRATION NO/DATE: 201 IS 106 F 3 19950907; FIRST REGISTRATION: LI 53014 19950220
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description